CD274 and triple-negative breast carcinoma: Although atezolizumab (selectively targeting PDL1 to prevent interaction with the receptors PD-1 and B7-1) plus nab-paclitaxel (as an inhibitor of microtubule depolymerization) is approved in advanced triple-negative breast cancer, the efficacy is limited.